GB Sciences, Inc. (GBLX)
OTCMKTS: GBLX · Delayed Price · USD
0.0118
-0.0003 (-2.48%)
May 24, 2024, 2:51 PM EDT - Market closed

Company Description

GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines.

The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market.

Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs.

The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016.

GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

GB Sciences, Inc.
Country United States
Industry Biotechnology
Sector Healthcare
Employees 3
CEO John Claybron Poss

Contact Details

Address:
6450 Cameron Street #110a
Las Vegas, Nevada 89118
United States
Phone (844) 843-2569
Website gbsciences.com

Stock Details

Ticker Symbol GBLX
Exchange OTCMKTS
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001165320
CUSIP Number 361544109
ISIN Number US3615441090
Employer ID 59-3733133
SIC Code 1311

Key Executives

Name Position
John Claybron Poss Chief Executive Officer, Interim Chief Financial Officer and Chairman
Dr. Andrea Small-Howard M.B.A., MBA, Ph.D. Chairman of Scientific Advisory Board, Chief Science Officer, President and Director
Gary R. Henrie Esq. Securities Counsel and Company Secretary

Latest SEC Filings

Date Type Title
Feb 12, 2024 10-Q Quarterly Report
Nov 20, 2023 10-Q Quarterly Report
Nov 14, 2023 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Oct 10, 2023 424B3 Prospectus
Sep 8, 2023 8-K Current Report
Aug 14, 2023 10-Q Quarterly Report
Aug 2, 2023 D Notice of Exempt Offering of Securities
Jul 14, 2023 10-K Annual Report
Jun 30, 2023 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Apr 14, 2023 8-K Current Report